Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

UCB SA Add to portfolio

N100:UCB, May 29, 10:30 UTC

Latest N100:UCB News

Filter your feed

Apply Filter

Thursday, April 02


News

UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

UCB

Financial guidance updated - The closing of this acquisition leads to an update of UCB’s 2020 financial guidance – as announced with the FY 2019 results press release on 20 February 2020. For 2020, UCB is aiming for revenues in the range of € 5.05 – 5.15 billion thanks to the current core product growth and new patient populations being served. Hence, the underlying profitability, rEBITDA, in the range of 26-27% of revenue, will reflect the high R&D investment level, including the investment for the Ra Pharma pipeline. The inclusion of Ra Pharma will be dilutive to UCB’s mid-term earnings level due to R&D investments. As a result, the mid-term target of UCB reaching a rEBITDA ratio (to revenue) of 31% moves to 2022 from 2021 as previously guided. About Ra Pharmaceuticals, Inc. Ra Pharma, now a wholly-owned subsidiary of UCB, is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

UCB

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB's FcRn targeting antibody which is also in phase 3. - Innovative research and development unit in Cambridge, MA adds to UCB's network and presence in Massachusetts and the greater Boston area of the U.S. - Total transaction cash value of approximately US$ 2.3 billion / € 2.1 billion based on US$ 48 in cash per Ra Pharma share and taking Ra Pharma cash and settlement of acquisition related expenses into consideration. Financial guidance updated - The closing of this acquisition leads to an update of UCB's 2020 financial guidance – as announced with the FY 2019 results press release on 20 February 2020. For 2020, UCB is aiming for revenues in the range of € 5.05 – 5.15 billion thanks to the current core product growth and new patient populations being served. About Ra Pharmaceuticals, Inc. Ra Pharma, now a wholly-owned subsidiary of UCB, is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, March 23


News

Global Hidradenitis Suppurativa (HS) Industry Assessment, 2020 Featuring InflaRx, Novartis Pharma, Incyte Corp, UCB Biopharma, and Janssen Pharma

UCB INCY

DUBLIN, March 23, 2020 /PRNewswire/ -- The "Hidradenitis Suppurativa (HS) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030. It also helps to understand the Hidradenitis Suppurativa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.Marketed DrugsHumira: AbbVieHumira (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Monday, March 02


News

UCB, Daiichi Sankyo to offer new treatment option for epilepsy

UCB

UCB Japan Co., Ltd, and Daiichi Sankyo Company, Limited are pleased to announce that a supplemental application for VIMPAT® (generic name: lacosamide) was filed in Japan to expand the indication for adjunctive therapy for tonic-clonic seizures in epilepsy patients as a partial change in approved items of the manufacturing and marketing approval. This application is based on the results of a multinational PIII clinical trial in 242 adult and pediatric epilepsy patients aged 4 years and older (including Japanese patients) with tonic-clonic seizures showing inadequate control under treatment with existing anti-epileptic drugs. The study met its primary endpoint (the time to the second tonic-clonic seizure during the 24-week evaluation period, i.e., the risk of developing the second tonic-clonic seizure) showing statistically significant difference between patients groups administered with lacosamide vs placebo. UCB and Daiichi Sankyo expect that they can contribute to patients by offering a new treatment option for epilepsy with this drug.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, February 20


News

UCB Full Year Report 2019

UCB

"2019 was a year of strong delivery and growth. Hence, we have updated the peak sales guidance for Cimzia® and Vimpat® and we continue to accelerate our investments into future growth drivers," said Jean-Christophe Tellier, CEO UCB. "Based on our promising late-stage pipeline and the pending Ra Pharma acquisition, we could potentially launch up to 7 products by 2025 to create patient value for specific populations now and into the future. Also, we focus on four sustainability areas that are critical to our long-term success and our contribution to society." In December, UCB launched Nayzilam®(midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S. Nayzilam® nasal spray was approved in the U.S. in May 2019. Keppra® (levetiracetam) for epilepsy, reported net sales of € 770 million, reflecting both, the strong, trusted brand and the maturity of the product. Operating expenses reached € 2 527 million (+9%; +6% CER) reflecting 15% higher marketing and selling expenses of € 1 108 million - driven by the launch of Cimzia® in psoriasis in the U.S. and Europe and in active non-radiographic axial spondyloarthritis (nr-axSpA) in the U.S. as well as launch preparations for Evenity® in Europe, 10% higher research and development expenses of € 1 272 million – driven by higher R&D investments and resulting in a R&D ratio of 26% in 2019 after 25% in 2018 and 8% higher general and administrative expenses of € 195 million, mainly in connection with the new organization model implemented in 2019.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, January 20


News

Transparency notification UCB SA/NV - UCB

UCB BLK

Transparency notification UCB SA/NVMon, Jan 20, 2020 20:10 CET. The transparency notification dated 20 January 2020 has been submitted in accordance with Article 18 juncto Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV and its affiliates crossed downwards the 3% threshold on 17 January 2020. Chain of controlled undertakings through which the holding is effectively held:. T +32.2.559.94.14 antje.witte@ucb.com.

Read Full Details

Topics:
  • Business
  • Financial
  • Fiancial
  • Politics

Tuesday, December 17


News

UCB and Accenture Collaborate to Accelerate Data Processing

UCB ACN

Accenture and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT Pharmacovigilance to accelerate processing of individual patient safety case reports. “Accenture INTIENT Pharmacovigilance will help us rapidly process data to identify potential events or issues, while reducing the time and cost needed to deliver a higher level of patient safety. Accenture’s INTIENT Pharmacovigilance leverages artificial intelligence to collect, manage and learn from UCB’s structured and unstructured source data within pharmacovigilance, which monitors the effects of drugs during clinical trials and after they have been cleared by regulators for use. An Accenture Life Sciences operations team is managing case processing augmented by the platform for UCB, allowing UCB’s case processing team to focus on value-add activities such as medical assessment and targeted follow up, helping them uncover insights into emerging trends, potential compliance issues and adverse events.

Read Full Details

Topics:
  • Business
  • Health
  • Science
  • Technology

Monday, December 16


News

UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety

UCB ACN

NEW YORK--(BUSINESS WIRE)--Accenture (NYSE:ACN) and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of individual patient safety case reports. Accenture’s INTIENT Pharmacovigilance leverages artificial intelligence to collect, manage and learn from UCB’s structured and unstructured source data within pharmacovigilance, which monitors the effects of drugs during clinical trials and after they have been cleared by regulators for use. An Accenture Life Sciences operations team is managing case processing augmented by the platform for UCB, allowing UCB’s case processing team to focus on value-add activities such as medical assessment and targeted follow up, helping them uncover insights into emerging trends, potential compliance issues and adverse events. “Accenture INTIENT Pharmacovigilance will help us rapidly process data to identify potential events or issues, while reducing the time and cost needed to deliver a higher level of patient safety.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Friday, December 13


News

Global Epilepsy Drugs Market 2019 – Abbott Laboratories , GlaxoSmithKline Plc , UCB , Cephalon , Johnson & Johnson , Pfizer – Industry News Releases

UCB ABT +3 more UCB ABT GSK GSK JNJ

Do Inquiry For More Details : http://www.mrsresearchgroup.com/report/137530#inquiry-for-buying. Chapter 1: Introduction, Definition, Specifications, Classification and Scope the Epilepsy Drugs market 2019Chapter 2: Exclusive Summery like Industry chain structure, Manufacturer cost structure, suppliers, etcChapter 3: Displays Trends, Drivers and Challenges of the Epilepsy Drugs marketChapter 4: By the study of SWOT analysis it displays sales analysis, investment analysis, market analysis, etcChapter 5: It evaluate the market by segments, by countries and by manufacturers with revenue, share and sales by key countries in these various regions.Chapter 6: Evaluate the leading manufacturers of the Global Epilepsy Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company ProfileChapter 7: Epilepsy Drugs Research Findings and Conclusion, Appendix, system and information source. The report provides data analyzed graphically for a better explanation. Our experts have crafted the full study of Epilepsy Drugs market 2019 in a structured format for better interpretation.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
  • Science

Tuesday, December 10


News

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB

ATLANTA, Dec. 9, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune thrombocytopenia (ITP). Clinically relevant improvements (i.e., reaching ≥50x109/L) in platelet count and decreases in immunoglobin G (IgG) levels were observed across all dose groups, with higher response rate (55–67% in 1 x 15 mg/kg and 1 x 20 mg/kg dose groups vs 36–45% in 5 x 4 mg/kg, 3 x 7 mg/kg and 2 x 10 mg/kg dose groups) and shorter time to response achieved by the 1 x 15 mg/kg and 1 x 20 mg/kg rozanolixizumab dose groups.i. "ITP is a severe, often chronic disease that can have a significant, long-term impact on people's health and quality of life. Despite approved therapies, there is still an urgent need for new treatment options that are well tolerated and provide a sustained increase in platelet count," said Professor Tadeusz Robak, Professor of Hematology at the Medical University of Lodz, Poland. Pathogenic IgG autoantibodies target platelets and megakaryocytes (platelet precursors), leading to the removal and destruction of both circulating and newly formed platelets[vi],[vii],[viii] ultimately resulting in a propensity for bleeding in patients with ITP.

Read Full Details

Topics:
  • Business
  • Health
  • Financial